Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2003
09/25/2003WO2003077874A2 Substituted tetrahydroisoquinoline compounds, methods of making, and their use
09/25/2003WO2003077869A2 Neuroprotective spirostenol pharmaceutical compositions
09/25/2003WO2003077867A2 Naltrexone hydrochloride compositions
09/25/2003WO2003077863A2 Method for overexpression of zwitterionic polysaccharides
09/25/2003WO2003077862A2 Potent, simplified derivatives of immunosuppressive agents
09/25/2003WO2003077860A2 BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
09/25/2003WO2003077857A2 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
09/25/2003WO2003077855A2 N3 alkylated benzimidazole derivatives as mek inhibitors
09/25/2003WO2003077850A2 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
09/25/2003WO2003077847A2 Substituted amides
09/25/2003WO2003077845A2 Compositions and methods for treating glaucoma and ocular hypertension
09/25/2003WO2003077842A2 Palatable oral suspension and method
09/25/2003WO2003077835A2 Sodium dodecyl sulfate compositions for inactivating prions
09/25/2003WO2003077834A2 Central airway administration for systemic delivery of therapeutics
09/25/2003WO2003077832A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003WO2003077831A2 Compositions and methods for treating mdma-induced toxicity
09/25/2003WO2003077830A2 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives
09/25/2003WO2003077828A2 Novel florfenicol-type antibiotics
09/25/2003WO2003077723A2 Methods and devices for detection and therapy of atheromatous plaque
09/25/2003WO2003077657A1 Choline-silicic acid complex with osmolytes and divalent trace elements
09/25/2003WO2003077656A1 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
09/25/2003WO2003077653A1 Autoinducer compounds
09/25/2003WO2003070738A3 Topiramate salts and compositions comprising and methods of making and using the same
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003068159A3 Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
09/25/2003WO2003061594A3 Methods and compositions for reducing the development of drug tolerance and/or physical dependence
09/25/2003WO2003061568A3 Methods and therapeutic compositions in the treatment of advanced cancer
09/25/2003WO2003059277A3 Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly
09/25/2003WO2003047552A3 Pharmaceutical composition comprising a 5ht1 receptor agonist
09/25/2003WO2003045434A3 Endothelin antagonists ina method and composition for potentiating an opiate analgesic
09/25/2003WO2003042411A3 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
09/25/2003WO2003041727A3 Plant derived or derivable material with appetite suppressing activity
09/25/2003WO2003040368A3 Pharmaceutical compositions of marine sponge microciona prolifera
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003039451A3 Thiazole pyridazinones as adenosine antagonists
09/25/2003WO2003037313A3 Methods for the treatment of addiction
09/25/2003WO2003035059A3 Spermicides
09/25/2003WO2003031643A9 Methods for regulating co-stimulatory molecule expression with reactive oxygen
09/25/2003WO2003029199A9 Benzene derivatives, process for preparing the same and use thereof
09/25/2003WO2003020219A3 Aerosolized decongestants for the treatment of sinusitis
09/25/2003WO2003018064A3 Lipophilic drug compositions
09/25/2003WO2003015690A3 Method for treating primary insomnia
09/25/2003WO2003013537A3 Irinotecan for treatment of cancer
09/25/2003WO2003013535A3 Use of irinotecan for improved treatment of cancer based on mdr1
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof
09/25/2003WO2003011249A3 Ophthalmic composition containing n-acetylcysteine for the treat ment of dry-eye syndrome
09/25/2003WO2003008454A3 Glycoprotein vi fusion proteins
09/25/2003WO2003007924A3 Combinations comprising epothilones and pharmaceutical uses thereof
09/25/2003WO2003002114A3 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
09/25/2003WO2003002108A3 Use of tyrosine kinase inhibitors for treating inflammatory diseases
09/25/2003WO2003001968A3 Compositions and methods for inhibiting platelet activation and thrombosis
09/25/2003WO2003000709A3 Sialic acid derivatives for use as siglec inhibitors
09/25/2003WO2002102981A3 SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
09/25/2003WO2002102375A3 Imidazole derivatives for modulating sodium channels
09/25/2003WO2002100827A9 Method for increasing the survival of dopamine secreting cells
09/25/2003WO2002100818A3 Aminediols as agents for the treatment of alzheimer's disease
09/25/2003WO2002100412A3 Stabilized dispersion of phytosterol in oil
09/25/2003WO2002098339A3 Zinc containing compositions for anti-viral use
09/25/2003WO2002097059A9 Chromosome-based platforms
09/25/2003WO2002096357A3 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
09/25/2003WO2002094287A3 Identifying parasitic fungi of the organism, and treatment thereof
09/25/2003WO2002094282A3 Compositions with methylprednisolone derivatives having therapeutic effect
09/25/2003WO2002092826A3 Composition and method for treating cancer using herpes virus
09/25/2003WO2002083112A3 Method for the treatment of polycystic kidney disease
09/25/2003WO2002080911A3 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
09/25/2003WO2002077263A3 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
09/25/2003WO2002076482A3 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS
09/25/2003WO2002074733A3 Tryptase-inhibitors
09/25/2003WO2002061128A3 Method of determining a chemotherapeutic regimen based on ercc1 expression
09/25/2003WO2002060392A3 Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
09/25/2003WO2002055688A8 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
09/25/2003WO2002046419A3 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
09/25/2003WO2002036573B1 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
09/25/2003WO2002032842A3 Compounds with high monoamine transporter affinity
09/25/2003WO2002030884A3 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002030882A3 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002030448A3 Treatment of demyelinating diseases by administering gpe
09/25/2003WO2002028432A3 Stem cell-based methods for preventing and treating tumor
09/25/2003WO2002028355A3 Methods and compositions for enhancing angiogenesis
09/25/2003WO2002024690A3 Efficient process for the preparation of a factor xa inhibitor
09/25/2003WO2002022115A3 Methods and compositions for treating nail fungus
09/25/2003WO2002017855A3 Process for preparing pharmaceutical compositions for use with soft gelatin formulations
09/25/2003WO2002015922A3 New uses for amino acid anticonvulsants for treatment of pain
09/25/2003WO2002013833A3 SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2
09/25/2003WO2002013807A3 Compounds for the treatment of addictive disorders
09/25/2003WO2002011670A3 Solid forms of tin ethyl etiopurpurin and processes for producing such forms
09/25/2003WO2002010378A3 Antisense modulation of ptp1b expression
09/25/2003WO2002004433A3 Melanin concentrating hormone receptor ligands
09/25/2003WO2002000240A3 Compositions and methods for treating females sexual response
09/25/2003WO2001093921A3 Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
09/25/2003US20030181847 For topical treatment of nail diseases (onychomycosis) after forming aperture in infected nail with laser beam; fungicides (terbinafine)
09/25/2003US20030181766 Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them
09/25/2003US20030181765 Reacting an azide compound with an amine to form an intermediate, reducting the azide of the intermediate to form amine; amidation, reduction of azide, azidation, blocking hydroxy group, lactonization and deblocking
09/25/2003US20030181764 Acylsulfonamide derivatives containing fluorosubstitutedphenylethynyl group having a hypoglycemic effect and free of the side effect
09/25/2003US20030181749 Unreacted relatively low molecular weight cyclic siloxanes and oligomers are removed from relatively high molecular weight sililcon oil or fluid by performing a supercritical carbon dioxide extraction of silicone oil
09/25/2003US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
09/25/2003US20030181720 Chemical intermediate for making fungicides; debromination, hydroxylation, formation/c-c/
09/25/2003US20030181716 Novel azepane derivatives
09/25/2003US20030181714 Oligosaccharide chain, which contianing a terminal NeuNAc alpha 6 linked to a linear or branched polylcatosamine type structure containing at least 3 lactosamine; a linear or branched structure with two lactosamine and one lactose